SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the second quarter ended June 30, 2017.
“Our commercial efforts continue to drive strong financial performance with solid market uptake for NUPLAZID in patients with Parkinson’s disease psychosis,” said Steve Davis, ACADIA’s President and Chief Executive Officer. “Following positive data from our Phase II study in Alzheimer’s disease psychosis and recently completed End-of-Phase II meeting with the FDA, we are excited to start our Phase III program in the next couple of months.”
During the second quarter of 2017, ACADIA generated $30.5 million of net product sales of NUPLAZID, which includes the one-time recognition of $3.6 million associated with the transition to the sell-in revenue recognition method of accounting from the sell-through method.
Starting with the second quarter of 2017, based on its determination it had sufficient volume of activity to reasonably estimate its allowances for rebates and chargebacks, ACADIA began to recognize revenue at the point of sale to its specialty pharmacy and specialty distributor partners, commonly referred to as the “sell-in” revenue recognition method. Previously, ACADIA had deferred the recognition of revenue until it obtained evidence that its specialty partners had dispensed the product to a patient or had sold the product to a government facility, long-term care pharmacy or in-patient hospital pharmacy. The $3.6 million one-time adjustment was deferred revenue as of March 31, 2017 and represents product held by specialty pharmacies and specialty distributors at such date.
For comparison purposes, the following table presents NUPLAZID’s pro forma quarterly net product sales under the sell-in method, if ACADIA had been able to reasonably estimate its allowances for rebates and chargebacks from the time of launch in May 2016.
|
Pro Forma Reconciliation of Sell-Through to Sell-In Method |
|||||||||||||||||
| (in millions) | Three Months Ended | ||||||||||||||||
| June 30, | September 30, | December 31, | March 31, | June 30, | |||||||||||||
| 2016 | 2016 | 2016 | 2017 | 2017 | |||||||||||||
| NUPLAZID net sales, as reported1 | $ | 0.1 | $ | 5.3 | $ | 12.0 | $ | 15.3 | $ | 30.5 | |||||||
| Difference2 | 0.4 | 1.2 | 0.5 | 1.5 | (3.6 | ) | |||||||||||
|
Pro forma NUPLAZID net sales, sell-in method |
$ | 0.5 | $ | 6.5 | $ | 12.5 | $ | 16.8 | $ | 26.9 | |||||||
|
1 |
Includes the net sales as previously reported for the quarterly periods through March 31, 2017 utilizing the sell-through revenue recognition method. | ||
|
2 |
Represents the impact of recognizing the deferred revenue at period-end, net of allowances for rebates and chargebacks, had the sales been recognized in the quarter which the product was delivered to the specialty pharmacies and distributors. | ||
Recent Highlights
- Conducted End-of-Phase II meeting with the FDA on the Alzheimer’s disease psychosis (AD Psychosis) program.
- Abstract of Phase II data with pimavanserin for AD Psychosis was accepted for presentation at the Clinical Trials on Alzheimer’s Disease meeting in early November 2017.
- Expanded penetration into the long-term care market with the deployment of an additional 25 long-term care specialists; ACADIA currently has approximately 155 total sales specialists.
- NUPLAZID nominated for the 11th Annual Prix Galien Award for Best Pharmaceutical Agent.
- ACADIA named to Forbes Magazine’s List of World’s Most Innovative Growth Companies.
- Continue to advance broad clinical development program with ongoing studies in Alzheimer’s disease agitation, schizophrenia inadequate response, schizophrenia negative symptoms, and major depressive disorder.
Financial Results
Revenue
Net product sales of NUPLAZID, which was first made
available for prescription starting in May 2016, were $30.5 million for
the three months ended June 30, 2017 compared to $0.1 million for the
three months ended June 30, 2016. For the six months ended June 30, 2017
and 2016, ACADIA reported NUPLAZID net product sales of $45.8 million
and $0.1 million, respectively.
Research and Development
Research and development expenses
for the three months ended June 30, 2017 were $34.2 million, compared to
$20.5 million for the same period of 2016. For the six months ended June
30, 2017 and 2016, research and development expenses were $69.6 million
and $43.3 million, respectively. The increase in research and
development expenses during the 2017 periods as compared to 2016 was
primarily due to increased clinical costs related to the schizophrenia
and depression studies ACADIA initiated in the fourth quarter of 2016.
The company also incurred additional personnel and related costs
associated with its expanded research and development organization
during 2017 as compared to 2016.
Selling, General and Administrative
Selling, general and
administrative expenses for the three months ended June 30, 2017 were
$61.5 million, compared to $50.8 million for the same period of 2016.
For the six months ended June 30, 2017 and 2016, selling, general and
administrative expenses were $127.3 million and $78.3 million,
respectively. The increase in selling, general and administrative
expenses during the 2017 periods as compared to 2016 was primarily due
to costs incurred to support ACADIA’s commercial activities for NUPLAZID.
Net Loss
For the three months ended June 30, 2017, ACADIA
reported a net loss of $67.4 million, or $0.55 per common share,
compared to a net loss of $71.3 million, or $0.63 per common share, for
the same period in 2016. The net losses for the three months ended June
30, 2017 and 2016 included $18.2 million and $13.9 million,
respectively, of non-cash stock-based compensation expense. For the six
months ended June 30, 2017, ACADIA reported a net loss of $155.3
million, or $1.27 per common share, compared to a net loss of $121.1
million, or $1.08 per common share, for the same period in 2016. The net
losses for the six months ended June 30, 2017 and 2016 included $33.8
million and $25.8 million, respectively, of non-cash stock-based
compensation expense.
Cash and Investments
At June 30, 2017, ACADIA’s cash, cash
equivalents, and investment securities totaled $417.3 million, compared
to $529.0 million at December 31, 2016.
2017 Financial Guidance
ACADIA expects that full-year
NUPLAZID net sales for 2017 will be between $105 million and $115
million.
Conference Call and Webcast Information
ACADIA management
will review its second quarter financial results and operations via
conference call and webcast later today at 5:00 p.m. Eastern Time. The
conference call may be accessed by dialing 844-821-1109 for participants
in the U.S. or Canada and 830-865-2550 for international callers
(reference passcode 12799639). A telephone replay of the conference call
may be accessed through August 22, 2017 by dialing 855-859-2056 for
callers in the U.S. or Canada and 404-537-3406 for international callers
(reference passcode 12799639). The conference call also will be webcast
live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there through August
22, 2017.
About NUPLAZID® (pimavanserin)
NUPLAZID
is the first and only FDA-approved treatment for hallucinations and
delusions associated with PD Psychosis. NUPLAZID is a non-dopaminergic,
selective serotonin inverse agonist preferentially targeting 5-HT2A receptors
that are thought to play an important role in PD Psychosis. NUPLAZID is
an oral medicine taken once a day with a recommended dose of 34 mg (two
17-mg tablets). ACADIA discovered this new chemical entity and holds
worldwide rights to develop and commercialize NUPLAZID.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical
company focused on the development and commercialization of innovative
medicines to address unmet medical needs in central nervous system
disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release
that are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to statements
related to guidance for fiscal year 2017 NUPLAZID net sales; the
benefits to be derived from NUPLAZID (pimavanserin); the utility of
pimavanserin in indications other than hallucinations and delusions
associated with PD Psychosis; and the timing or results of future
studies involving pimavanserin. These statements are only predictions
based on current information and expectations and involve a number of
risks and uncertainties. Actual events or results may differ materially
from those projected in any of such statements due to various factors,
including the uncertainty of future commercial sales and related items
that would impact net sales for 2017, the risks and uncertainties
inherent in drug discovery, development, approval and commercialization,
and the fact that past results of clinical trials may not be indicative
of future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year ended
December 31, 2016 as well as ACADIA’s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
|
ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (Unaudited) |
|||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||||
| Revenues | |||||||||||||||||
| Product sales, net | $ | 30,475 |
$ |
97 |
$ |
45,761 | $ | 97 | |||||||||
| Collaborative revenue | — | — | — | 4 | |||||||||||||
| Total revenues | 30,475 | 97 | 45,761 | 101 | |||||||||||||
| Operating expenses | |||||||||||||||||
| Cost of product sales | 2,224 | 526 | 4,487 | 526 | |||||||||||||
| License fees and royalties | 982 | 248 | 1,657 | 248 | |||||||||||||
| Research and development | 34,180 | 20,478 | 69,589 | 43,253 | |||||||||||||
| Selling, general and administrative | 61,523 | 50,768 | 127,268 | 78,259 | |||||||||||||
| Total operating expenses | 98,909 | 72,020 | 203,001 | 122,286 | |||||||||||||
| Loss from operations | (68,434 | ) | (71,923 | ) | (157,240 | ) | (122,185 | ) | |||||||||
| Interest income, net | 993 | 601 | 1,956 | 1,101 | |||||||||||||
| Net loss | $ | (67,441 | ) | $ | (71,322 | ) | $ | (155,284 | ) | $ | (121,084 | ) | |||||
| Net loss per common share, basic and diluted | $ | (0.55 | ) | $ | (0.63 | ) | $ | (1.27 | ) | $ | (1.08 | ) | |||||
| Weighted average common shares outstanding, basic and diluted | 122,122 | 113,308 | 121,888 | 112,327 | |||||||||||||
|
ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
||||||||
|
June 30,
2017 |
December 31,
2016 |
|||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Cash, cash equivalents and investments | $ | 417,320 | $ | 529,036 | ||||
| Accounts receivable, net | 11,594 | 5,903 | ||||||
| Interest and other receivables | 784 | 1,237 | ||||||
| Inventory | 6,003 | 4,175 | ||||||
| Prepaid expenses | 8,044 | 7,546 | ||||||
| Total current assets | 443,745 | 547,897 | ||||||
| Property and equipment, net | 3,296 | 3,081 | ||||||
| Intangible assets, net | 6,277 | 7,015 | ||||||
| Restricted cash | 2,475 | 2,375 | ||||||
| Other assets | 522 | 785 | ||||||
| Total assets | $ | 456,315 | $ | 561,153 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Accounts payable | $ | 3,588 | $ | 3,912 | ||||
| Accrued liabilities | 37,325 | 36,029 | ||||||
| Deferred revenue | — | 2,644 | ||||||
| Total current liabilities | 40,913 | 42,585 | ||||||
| Long-term liabilities | 262 | 157 | ||||||
| Total liabilities | 41,175 | 42,742 | ||||||
| Total stockholders’ equity | 415,140 | 518,411 | ||||||
| Total liabilities and stockholders’ equity | $ | 456,315 | $ | 561,153 | ||||
Important Safety Information and Indication for
NUPLAZID (pimavanserin) tablets
WARNING: INCREASED
MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly
patients with dementia-related psychosis treated with antipsychotic
drugs are at an increased risk of death. NUPLAZID is not approved for
the treatment of patients with dementia-related psychosis unrelated to
the hallucinations and delusions associated with Parkinson’s disease
psychosis.
NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Contraindication: NUPLAZID is contraindicated in patients with a history of hypersensitivity reaction to pimavanserin or any of its components. Reactions have included rash, urticaria, tongue swelling, circumoral edema, and throat tightness.
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half. Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced efficacy. Increase in NUPLAZID dosage may be needed.
Renal Impairment: No dosage adjustment for NUPLAZID is needed in patients with mild to moderate renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment.
Hepatic Impairment: Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.
Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and should therefore be used in pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.
Pediatric Use: Safety and efficacy have not been established in pediatric patients.
Dosage and Administration: Recommended dose: 34 mg per day, taken orally as two 17-mg tablets once daily, without titration.
For additional Important Safety Information, including boxed warning, please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170808006350/en/
